|
|
BECC438b |
|
Vaxjo ID |
123 |
|
Vaccine Adjuvant Name |
BECC438b |
|
Adjuvant VO ID |
VO_0005298
|
|
Description |
small molecule with TLR4 receptor that induces Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (University of Maryland, Baltimore) |
|
Host Species for Testing |
Mouse |
|
Components |
novel bacterial enzymatic combinatorial chemistry (BECC)-derived toll-like receptor 4 (TLR4) agonists and the aluminum hydroxide adjuvant Alhydrogel (did not always include Alhydrogel .. dependent on experimental study) |
|
Preparation |
novel TLR4Ls were generated by BECC mutations in Yersinia pestis strain KIM6+ (pCD1−), an attenuated (BSL2) strain |
|
Function |
Induces mucosal immunity, induces epitope spreading |
| References |
(Ernst, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=31]
Howlader et al., 2021: Howlader DR, Das S, Lu T, Hu G, Varisco DJ, Dietz ZK, Walton SP, Ratnakaram SSK, Gardner FM, Ernst RK, Picking WD, Picking WL. Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas Aeruginosa. Frontiers in pharmacology. 2021; 12; 706157. [PubMed: 34483911].
Howlader et al., 2024: Howlader DR, Mandal RS, Lu T, Maiti S, Dietz ZK, Das S, Whittier SK, Nagel AC, Biswas S, Varisco DJ, Gardner FM, Ernst RK, Picking WD, Picking WL. Development of a nano-emulsion based multivalent protein subunit vaccine against Pseudomonas aeruginosa. Frontiers in immunology. 2024; 15; 1372349. [PubMed: 38698863].
|
|
